Vaccination during a pandemic - a public health challenge

Published

2020-12-31

DOI:

https://doi.org/10.47203/IJCH.2020.v32i04.001

Keywords:

public health challenge

Dimensions Badge

Issue

Section

Editorial

Authors

  • Faruqueuddin Ahmed Khaja Bandanawaz University, Kalaburagi, Karnataka

Abstract

Since the emergence of COVID 19 virus, scientists all over the world are working at breakneck speed to develop a vaccine. Development of a vaccine is not a competitive race to the finish as it must pass through a stringent process of evaluation. The process includes vaccines’ immunogenicity, duration of immunity, efficacy of protection, interaction with other antigens, dosage, route of administration, packaging, and thermostability and expected adverse events and safety. Efficacy of a new vaccine is measured in clinical trials under ideal conditions, whereas its effectiveness is measured in the field under actual program conditions. (1) In normal circumstances, vaccine development is a prolonged process, averaging over 10 years from start to finish (2). To meet the urgent, need a COVID 19 vaccine may be available in a much shorter-term frame, at the earliest in 18 months.

How to Cite

1.
Ahmed F. Vaccination during a pandemic - a public health challenge. Indian J Community Health [Internet]. 2020 Dec. 31 [cited 2022 Oct. 4];32(4):617-9. Available from: https://iapsmupuk.org/journal/index.php/IJCH/article/view/1899

Downloads

Download data is not yet available.

References

Field Guide_ New Vaccine 1st. Edition, Scientific & Technical Publication No632, Pan American Health Organization, Washington 2010. https://www.paho.org/hq/dmdocuments/2010/FieldGuide_NewVaccines_1stEd_e.pdf? Accessed on August 27, 2020.

Thanh Le T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020; published online April 9.DOI:10.1038/d41573-020-00073-5. Accessed on July29 2020

Pronker ES, Weenen TC, Commandeur H, Claassen EH, Osterhaus AD. Risk in vaccine research and development quantified. PLoS One. 2013;8(3):e57755. doi: 10.1371/journal.pone.0057755. Epub 2013 Mar 20. PMID: 23526951; PMCID: PMC3603987.[PubMed].

Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity. 2020 Apr 14;52(4):583-589. doi: 10.1016/j.immuni.2020.03.007. Epub 2020 Apr 6. PMID: 32259480; PMCID: PMC7136867.[PubMed].

Eyal N, Lipsitch M, Smith PG. Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure. J Infect Dis. 2020 May 11;221(11):1752-1756. doi:10.1093/infdis/jiaa152. PMID: 32232474; PMCID: PMC7184325.[PubMed].

Development and Licensure of Vaccines to Prevent COVID. 19 Guidance for industry. US Food and Drug Administration. June 2020.https://fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19. Accessed on August 10, 2020.

Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R; World Health Organization Solidarity Vaccines Trial Expert Group. COVID-19 vaccine trials should seek worthwhile efficacy. Lancet. 2020 Sep 12;396(10253):741-743. doi: 10.1016/S0140-6736(20)31821-3. Epub 2020 Aug 27. PMID: 32861315; PMCID: PMC7832749.[PubMed].

Pandemic-situation-and vaccine delivery- distribution-and -adminstration -551929; Prime Minister’s Office [email protected] dated 21-102020.

Philip R. Krause, M.D., and Marion F. Gruber, Ph.D. The New England Journal of Medicine. 16th. October. https://www.nejm.org/toc/nejm/383/16, Accessed on October 24, 2020.